Image via Wikipedia
In the decades-long war on cancer, as of late, researchers had been making little progress in comparison to colleagues treating other conditions, such as cardiac or infectious diseases. “Cancer research has really plateaued out,” William Matsui, an associate professor of oncology at Johns Hopkins University‘s School of Medicine, said at the 2009 World Stem Cell Summit here on Tuesday. But pushing cancer stem cell research “gives us a novel way to study cancer,” said Matsui, who also runs a lab at the university’s Sidney Kimmel Comprehensive Cancer Center.
Cancer and stem cells have had a fraught relationship—not in
The drug metformin, a mainstay of diabetes care for 15 years, may have a new life as a cancer treatment, researchers said.
In a study in mice, low doses of the drug, combined with a widely used chemotherapy called doxorubicin, shrank breast-cancer tumors and prevented their recurrence more effectively than chemotherapy alone.
The findings add to a growing body of evidence that metformin, marketed as Glugophase by Bristol-Myers Squibb Co. and available in generic versions, could be a potent antitumor medicine.
They also lend support to an emerging theory that cancer’s ability to survive and resist therapy is regulated by cancer stem
SANUWAVE Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific findings titled “Extracorporeal Shock Wave Stimulation of Osteoprogenitor Cells” were presented at the 2009 International Bone-Tissue-Engineering Congress (“Bone-Tec”) in Hannover, Germany, which was held October 9-11, 2009.
Dr. Myron Spector, PhD, Professor of Orthopaedic Surgery (Biomaterials) at Harvard Medical School, Director of Orthopaedic Research at Brigham and Women’s Hospital and Director of Tissue Engineering at VA Boston Healthcare System, was an invited guest speaker at the Conference. The
Harvard scientists at Dana-Farber Cancer Institute say they have for the first time partially reversed age-related degeneration in mice, resulting in new growth of the brain and testes, improved fertility, and the return of a lost cognitive function.
In a report posted online by the journal Nature in advance of print publication, researchers led by Ronald A. DePinho, a Harvard Medical School (HMS) professor of genetics, said they achieved the milestone in aging science by engineering mice with a controllable telomerase gene. The telomerase enzyme maintains the protective caps called telomeres that shield the ends of chromosomes.
As humans age, low
Shelley Brown was pointing toward a life of cutting-edge stem cell research. Then one day in 2010, she says, she encountered the divine.
“Something was moving, and I thought I must have hit the petri dish by accident,” said Brown, who had been trying to direct a set of stem cells toward bone cells during her Ph.D. work in biomedical engineering at the University of Michigan. “When I looked closer under the microscope, I realized the cells were beating. They had spontaneously differentiated into electrically coupled, beating heart cells. That’s when I felt at the mercy of God, and that’s